Cover Image
市場調查報告書

胚胎著床前檢驗的全球市場預測 2022年:胚胎著床前診斷 (PGD) /胚胎著床前篩檢 (PGS),NGS,PCR,FISH,CGH,SNP

Preimplantation Genetic Testing Market by Type (Genetic Diagnosis/Genetic Screening), Technology (NGS, PCR, FISH, CGH, SNP), Products & Services, Application (Aneuploidy, Translocations), End User (Fertility Clinics, Research) - Forecast to 2022

出版商 MarketsandMarkets 商品編碼 529937
出版日期 內容資訊 英文 198 Pages
訂單完成後即時交付
價格
Back to Top
胚胎著床前檢驗的全球市場預測 2022年:胚胎著床前診斷 (PGD) /胚胎著床前篩檢 (PGS),NGS,PCR,FISH,CGH,SNP Preimplantation Genetic Testing Market by Type (Genetic Diagnosis/Genetic Screening), Technology (NGS, PCR, FISH, CGH, SNP), Products & Services, Application (Aneuploidy, Translocations), End User (Fertility Clinics, Research) - Forecast to 2022
出版日期: 2017年07月13日 內容資訊: 英文 198 Pages
簡介

全球胚胎著床前檢驗市場規模,預計從2017年的3億3,640萬美元,到2022年達5億4,180萬美元,以10.0%的年複合成長率擴大。全球性不孕率的增加,胚胎著床前檢驗領域的公民營投資增加,全球性不孕治療院數的增加,遺傳基因分析領域的技術進步,及母性年齡上升使胎兒染色體異常風險高等,成為促進該市場成長的主要因素。

本報告提供全球胚胎著床前檢驗市場相關調查分析,市場概要,產業趨勢,各市場區隔的市場分析,競爭情形,主要企業等相關的系統性資訊。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 胚胎著床前診斷、篩檢:市場概要
  • 地區分析:胚胎著床前遺傳基因診斷、篩檢,各技術
  • 胚胎著床前診斷、篩檢市場:各應用領域
  • 胚胎著床前診斷、篩檢市場:各產品與服務
  • 胚胎著床前診斷、篩檢市場地區概要

第5章 市場概要

  • 簡介
  • 市場發展:胚胎著床前診斷、篩檢技術
  • 市場動態
    • 主要的市場成長的推動要素
    • 主要的阻礙市場成長要素
    • 主要市場機會
    • 主要市場課題

第6章 產業考察

  • 價值鏈分析
  • 波特的五力分析
  • 法規情形

第7章 胚胎著床前診斷、篩檢市場:各治療類型

  • 簡介
  • 胚胎著床前篩檢 (PGS)
  • 胚胎著床前診斷 (PGD)

第8章 胚胎著床前診斷、篩檢市場:各技術

  • 簡介
  • 次世代定序
  • 聚合酵素鏈鎖反應
  • 螢光原位雜合反應
  • 比較基因雜合反應
  • 一鹼多型 (SNP)

第9章 胚胎著床前診斷、篩檢市場:各產品與服務

  • 簡介
  • 試劑、消耗品
  • 設備類
  • 軟體、服務

第10章 胚胎著床前診斷、篩檢市場:各應用領域

  • 地區分析
  • 簡介
  • 非整倍體
  • 染色體結構異常
  • 單一遺傳基因疾病
  • X連鎖遺傳病
  • HLA型檢測
  • 性別鑑定

第11章 胚胎著床前診斷、篩檢市場:各終端用戶

  • 簡介
  • 助產院 & 不孕治療院
  • 醫院,診斷實驗室及服務供應商
  • 研究實驗室 & 大學機關

第12章 胚胎著床前診斷、篩檢市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 其他

第13章 競爭情形

  • 簡介
  • 主要企業
  • 競爭情形、趨勢
  • 全球胚胎著床前遺傳基因診斷、篩檢市場上競爭領導製圖
  • 競爭領導製圖

第14章 企業簡介

  • 主要的產品廠商
    • ILLUMINA, INC.
    • THERMO FISHER SCIENTIFIC INC.
    • AGILENT TECHNOLOGIES, INC.
    • PERKINELMER, INC.
    • COOPERSURGICAL, INC. (THE COOPER COMPANIES, INC.子公司)
    • ABBOTT LABORATORIES
    • NATERA, INC. 166
    • RUBICON GENOMICS (TAKARA BIO USA HOLDINGS, INC.子公司)
    • OXFORD GENE TECHNOLOGY
    • YIKON GENOMICS
    • SCIGENE
  • 主要的服務供應商
    • BEIJING GENOMICS INSTITUTE
    • GOOD START GENETICS, INC.
    • INVICTA GENETICS
    • COMBIMATRIX CORPORATION
    • GENEA LIMITED
    • PROGENESIS

第15章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BT 5411

"Preimplantation genetic testing market projected to grow at a CAGR of 10.0%"

The global preimplantation genetic testing market is expected to reach USD 541.8 million by 2022 from USD 336.4 million in 2017, at a CAGR of 10.0%. Growing rate of infertility across the globe, increasing public-private investments in the field of preimplantation genetic testing, rising number of fertility clinics worldwide, technological advancements in the field of genetic analysis, and high risk of chromosomal abnormalities in the fetus with increasing maternal age are some of the key factors driving the growth of this market. However, the high procedural cost associated with preimplantation genetic testing and unsupportive government regulations are the factors restraining the growth of this market

"Next-generation Sequencing is expected to grow at the highest CAGR during 2017 to 2022"

By technology, the preimplantation genetic testing market covers next-generation sequencing (NGS), polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and single-nucleotide polymorphism (SNP). The NGS segment is expected to grow at the highest CAGR during 2017 to 2022, owing to benefits like reduced cost, better ability to detect an embryo with differing results (mosaicism), enhanced detection of structural abnormalities such as chromosomes with missing or duplicate segments, and reduction in human errors due to increased automation.

"The maternity centers & fertility clinics to dominate the global preimplantation genetic testing market during the forecast period"

On the basis of end users, the preimplantation genetic testing market is segmented into maternity centers & fertility clinics; hospitals, diagnostic labs, and service providers; and research laboratories & academic institutes. The maternity centers & fertility clinics segment accounted for the largest share of the global preimplantation genetic testing market in 2016 owing to the high success rate of treatments at fertility centers.

"APAC is projected to witness the highest growth during the forecast period "

While North America accounted for the largest share of the market in 2016, Asia-Pacific is expected to register the highest growth rate during the forecast period from 2017 to 2022. This is owing to the focus of key market players in this region, growing number of ART & IVF procedures in the region, continuous decline in average fertility rate, government initiatives for expansion and modernization of healthcare infrastructure across respective countries, and growing medical tourism across APAC countries.

Breakdown of supply-side primary interviews: by company type, designation, and region:

  • By Company Type - Tier 1 -50%, Tier 2 -33% and Tier 3 -17%
  • By Designation - C level - 17%, Director level - 50%, Others - 33%
  • By Region - North America - 34%, Europe - 26%, APAC - 35%, RoW - 5%

The major players in the market are Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Beijing Genomics Institute (BGI) (China), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Genea Limited (Australia), Rubicon Genomics, Inc. (U.S.), and Oxford Gene Technology (U.K.), among others.

Research Coverage:

This report studies the preimplantation genetic testing market based on technology, product & service, procedure type, application, and end user. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It evaluates opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total market. The report forecasts the revenue of the market segments with respect to four main regions.

Reasons to Buy the Report:

This research focuses on various levels of analysis-industry trends, vendor dive analysis of 25 market players, and company profiles of top 15 market players-which together comprise and discuss basic views on the competitive landscape, emerging and high-growth segments of the preimplantation genetic testing market, and high-growth regions and countries and their respective drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on business strategies adopted by the major players in the preimplantation genetic testing market. The report analyzes the preimplantation genetic testing market based on technology, product & service, procedure type, application, end user, and region
  • Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and product launches in the preimplantation genetic testing market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various preimplantation genetic testing products across geographies
  • Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the preimplantation genetic testing market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products and services, distribution networks, and manufacturing capabilities of leading players in the preimplantation genetic testing market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKETS COVERED
    • 1.3.1. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY USED
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH METHODOLOGY STEPS
    • 2.1.1. SECONDARY RESEARCH
      • 2.1.1.1. Key data from secondary sources
    • 2.1.2. PRIMARY RESEARCH
      • 2.1.2.1. Breakdown of primaries
      • 2.1.2.2. Key data from primary sources
    • 2.1.3. MARKET SIZE ESTIMATION
      • 2.1.3.1. Research methodology: bottom-up approach
      • 2.1.3.2. Research methodology: top-down approach
  • 2.2. RESEARCH DESIGN
  • 2.3. DATA VALIDATION AND TRIANGULATION
    • 2.3.1. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. PGDS MARKET OVERVIEW
  • 4.2. GEOGRAPHIC ANALYSIS: PGDS MARKET SHARE, BY REGION AND TECHNOLOGY, 2016
  • 4.3. PGDS MARKET, BY APPLICATION, 2017-2022
  • 4.4. PGDS MARKET SHARE, BY PRODUCT & SERVICE, 2017-2022
  • 4.5. GLOBAL PGDS MARKET: GEOGRAPHICAL SNAPSHOT, 2017-2022

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET EVOLUTION: PGDS TECHNOLOGIES
  • 5.3. MARKET DYNAMICS
    • 5.3.1. MAJOR MARKET DRIVERS
      • 5.3.1.1. Declining fertility rates worldwide
      • 5.3.1.2. Increasing public-private investments in preimplantation genetic testing
      • 5.3.1.3. Rising number of fertility clinics worldwide
      • 5.3.1.4. Technological advancements in genetic analysis
      • 5.3.1.5. High risk of chromosomal abnormalities with advancing maternal age
    • 5.3.2. MAJOR MARKET RESTRAINTS
      • 5.3.2.1. High procedural cost associated with preimplantation genetic testing
      • 5.3.2.2. Unfavorable government regulations
    • 5.3.3. MAJOR MARKET OPPORTUNITIES
      • 5.3.3.1. Growth opportunities in emerging markets
        • 5.3.3.1.1. Improving healthcare infrastructure
        • 5.3.3.1.2. Growing medical tourism industry
        • 5.3.3.1.3. Growth initiatives by key market players
      • 5.3.3.2. Growing awareness of assisted reproduction techniques
    • 5.3.4. MAJOR MARKET CHALLENGES
      • 5.3.4.1. Socioethical concerns surrounding preimplantation genetic testing
      • 5.3.4.2. Procedural limitations of preimplantation genetic testing with advancing age

6. INDUSTRY INSIGHTS

  • 6.1. VALUE CHAIN ANALYSIS
  • 6.2. PORTER'S FIVE FORCES ANALYSIS
  • 6.3. REGULATORY SCENARIO

7. PGDS MARKET, BY PROCEDURE TYPE

  • 7.1. INTRODUCTION
  • 7.2. PREIMPLANTATION GENETIC SCREENING (PGS)
  • 7.3. PREIMPLANTATION GENETIC DIAGNOSIS (PGS)

8. PGDS MARKET, BY TECHNOLOGY

  • 8.1. INTRODUCTION
  • 8.2. NEXT-GENERATION SEQUENCING (NGS)
  • 8.3. POLYMERASE CHAIN REACTION (PCR)
  • 8.4. FLUORESCENCE IN SITU HYBRIDIZATION (FISH)
  • 8.5. COMPARATIVE GENOMIC HYBRIDIZATION (CGH)
  • 8.6. SINGLE-NUCLEOTIDE POLYMORPHISM (SNP)

9. PGDS MARKET, BY PRODUCT AND SERVICE

  • 9.1. INTRODUCTION
  • 9.2. REAGENTS AND CONSUMABLES
  • 9.3. INSTRUMENTS
  • 9.4. SOFTWARE AND SERVICES

10. PGDS MARKET, BY APPLICATION

  • 10.1. INTRODUCTION
  • 10.2. ANEUPLOIDY
  • 10.3. STRUCTURAL CHROMOSOMAL ABNORMALITIES
    • 10.3.1. TRANSLOCATIONS
    • 10.3.2. DELETIONS
    • 10.3.3. DUPLICATIONS
    • 10.3.4. INVERSIONS
  • 10.4. SINGLE GENE DISORDERS
  • 10.5. X-LINKED DISORDERS
  • 10.6. HLA TYPING
  • 10.7. GENDER IDENTIFICATION

11. PGDS MARKET, BY END-USER

  • 11.1. INTRODUCTION
  • 11.2. MATERNITY CENTERS & FERTILITY CLINICS
  • 11.3. HOSPITALS, DIAGNOSTIC LABS, AND SERVICE PROVIDERS
  • 11.4. RESEARCH LABORATORIES & ACADEMIC INSTITUTES

12. PGDS MARKET, BY REGION

  • 12.1. INTRODUCTION
  • 12.2. NORTH AMERICA
    • 12.2.1. U.S.
    • 12.2.2. CANADA
  • 12.3. EUROPE
    • 12.3.1. GERMANY
    • 12.3.2. U.K.
    • 12.3.3. FRANCE
    • 12.3.4. REST OF EUROPE (ROE)
  • 12.4. ASIA-PACIFIC
    • 12.4.1. CHINA
    • 12.4.2. JAPAN
    • 12.4.3. INDIA
    • 12.4.4. REST OF ASIA-PACIFIC (ROAPAC)
  • 12.5. REST OF THE WORLD (ROW)

13. COMPETITIVE LANDSCAPE

  • 13.1. INTRODUCTION
  • 13.2. LEADING PLAYERS IN PGDS MARKET
  • 13.3. COMPETITIVE SITUATION AND TRENDS
    • 13.3.1. AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
    • 13.3.2. PRODUCT LAUNCHES AND APPROVALS
    • 13.3.3. ACQUISITIONS
    • 13.3.4. EXPANSIONS
    • 13.3.5. OTHER DEVELOPMENTS
  • 13.4. GLOBAL PGDS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2017
    • 13.4.1. VISIONARY LEADERS
    • 13.4.2. INNOVATORS
    • 13.4.3. DYNAMIC DIFFERENTIATORS
    • 13.4.4. EMERGING COMPANIES
  • 13.5. COMPETITIVE LEADERSHIP MAPPING
    • 13.5.1. STRENGTH OF PRODUCT PORTFOLIO (FOR 25 PLAYERS)
    • 13.5.2. BUSINESS STRATEGY EXCELLENCE (FOR 25 PLAYERS)

14. COMPANY PROFILES (Overview, Strength of Product Portfolio, Business Strategy Excellence, Products Offering, and Recent Developments)*

  • 14.1. TOP PRODUCT MANUFACTURERS
    • 14.1.1. ILLUMINA, INC.
    • 14.1.2. THERMO FISHER SCIENTIFIC INC.
    • 14.1.3. AGILENT TECHNOLOGIES, INC.
    • 14.1.4. PERKINELMER, INC.
    • 14.1.5. COOPERSURGICAL, INC. (A SUBSIDIARY OF THE COOPER COMPANIES, INC.)
    • 14.1.6. ABBOTT LABORATORIES
    • 14.1.7. NATERA, INC.
    • 14.1.8. RUBICON GENOMICS (A SUBSIDIARY OF TAKARA BIO USA HOLDINGS, INC.)
    • 14.1.9. OXFORD GENE TECHNOLOGY
    • 14.1.10. YIKON GENOMICS
    • 14.1.11. SCIGENE
  • 14.2. TOP SERVICE PROVIDER COMPANIES
    • 14.2.1. BEIJING GENOMICS INSTITUTE
    • 14.2.2. GOOD START GENETICS, INC.
    • 14.2.3. INVICTA GENETICS
    • 14.2.4. COMBIMATRIX CORPORATION
    • 14.2.5. GENEA LIMITED
    • 14.2.6. PROGENESIS

*Details on Overview, Strength of Product Portfolio, Business Strategy Excellence, Products Offering, and Recent Developments might not be captured in case of unlisted companies.

15. APPENDIX

  • 15.1. INSIGHTS OF INDUSTRY EXPERTS
  • 15.2. DISCUSSION GUIDE
  • 15.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 15.5. AVAILABLE CUSTOMIZATIONS
  • 15.6. RELATED REPORTS
  • 15.7. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: PGDS PRODUCT LAUNCHES, 2014-2017
  • TABLE 2: GLOBAL INCIDENCE RATE OF TRISOMY, 2014
  • TABLE 3: INCIDENCE RATE OF TRISOMY 21 IN THE U.S., 2014
  • TABLE 4: PROCEDURAL COSTS FOR PGD & PGS TESTING ACROSS THE WORLD'S MAJOR COUNTRIES/REGIONS, 2016
  • TABLE 5: AVERAGE COST OF PGS-IVF PROCEDURES IN THE U.S., 2016
  • TABLE 6: PUBLIC HEALTHCARE EXPENDITURE (% OF ANNUAL GDP): 2005 VS. 2014
  • TABLE 7: GLOBAL PGDS REGULATIONS, 2016
  • TABLE 8: GLOBAL PGDS MARKET SIZE, BY PROCEDURE TYPE, 2015-2022 (USD MILLION)
  • TABLE 9: PGS PROCEDURE TYPE: PGDS MARKET SIZE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 10: PGD PROCEDURE TYPE: PGDS MARKET SIZE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 11: PGDS MARKET SIZE, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 12: NGS TECHNOLOGY: PGDS MARKET SIZE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 13: PCR TECHNOLOGY: PGDS MARKET SIZE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 14: FISH TECHNOLOGY: PGDS MARKET SIZE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 15: CGH TECHNOLOGY: PGDS MARKET SIZE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 16: SNP TECHNOLOGY: PGDS MARKET SIZE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 17: PGDS MARKET SIZE, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 18: REAGENTS AND CONSUMABLES: PGDS MARKET SIZE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 19: INSTRUMENTS: PGDS MARKET SIZE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 20: SOFTWARE AND SERVICES: PGDS MARKET SIZE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 21: PGDS MARKET SIZE, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 22: ACCURACY RATE OF PGS TECHNIQUES FOR ANEUPLOIDY
  • TABLE 23: ANEUPLOIDY APPLICATION: PGDS MARKET SIZE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 24: STRUCTURAL CHROMOSOMAL ABNORMALITIES APPLICATION: PGDS MARKET SIZE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 25: STRUCTURAL CHROMOSOMAL ABNORMALITIES APPLICATION: PGDS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 26: TRANSLOCATIONS APPLICATION: PGDS STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET SIZE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 27: DELETIONS APPLICATION: PGDS STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET SIZE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 28: DUPLICATIONS APPLICATION: PGDS STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET SIZE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 29: INVERSIONS APPLICATION: PGDS STRUCTURAL CHROMOSOMAL ABNORMALITIES MARKET SIZE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 30: SINGLE GENE DISORDERS APPLICATION: PGDS MARKET SIZE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 31: X-LINKED DISORDERS APPLICATION: PGDS MARKET SIZE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 32: HLA TYPING APPLICATION: PGDS MARKET SIZE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 33: GENDER IDENTIFICATION APPLICATION: PGDS MARKET SIZE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 34: PGDS MARKET SIZE, BY END-USER, 2015-2022 (USD MILLION)
  • TABLE 35: MATERNITY CENTERS & FERTILITY CLINICS END-USER: PGDS MARKET SIZE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 36: HOSPITALS, DIAGNOSTIC LABS, AND SERVICE PROVIDERS END-USER: PGDS MARKET SIZE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 37: RESEARCH LABORATORIES & ACADEMIC INSTITUTES END-USER: PGDS MARKET SIZE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 38: GLOBAL PGDS MARKET SIZE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 39: NORTH AMERICA: MAJOR PGD AND PGS PRODUCT MANUFACTURERS AND SERVICE PROVIDERS
  • TABLE 40: NORTH AMERICA: PGDS MARKET SIZE, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 41: NORTH AMERICA: PGDS MARKET SIZE, BY PROCEDURE TYPE, 2015-2022 (USD MILLION)
  • TABLE 42: NORTH AMERICA: PGDS MARKET SIZE, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 43: NORTH AMERICA: PGDS MARKET SIZE, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 44: NORTH AMERICA: PGDS MARKET SIZE, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 45: NORTH AMERICA: PGDS MARKET SIZE FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 46: NORTH AMERICA: PGDS MARKET SIZE, BY END-USER, 2015-2022 (USD MILLION)
  • TABLE 47: U.S. REGULATIONS FOR INFERTILITY TREATMENT PROCEDURES
  • TABLE 48: U.S.: PGDS MARKET SIZE, BY PROCEDURE TYPE, 2015-2022 (USD MILLION)
  • TABLE 49: CANADIAN LAWS ON INFERTILITY TREATMENT PROCEDURES (AS OF 2016)
  • TABLE 50: CANADA: PGDS MARKET SIZE, BY PROCEDURE TYPE, 2015-2022 (USD MILLION)
  • TABLE 51: EUROPE: MAJOR PGD AND PGS PRODUCT MANUFACTURERS AND SERVICE PROVIDERS
  • TABLE 52: EUROPE: PGDS MARKET SIZE, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 53: EUROPE: PGDS MARKET SIZE, BY PROCEDURE TYPE, 2015-2022 (USD MILLION)
  • TABLE 54: EUROPE: PGDS MARKET SIZE, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 55: EUROPE: PGDS MARKET SIZE, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 56: EUROPE: PGDS MARKET SIZE, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 57: EUROPE: PGDS MARKET SIZE FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 58: EUROPE: PGDS MARKET SIZE, BY END-USER, 2015-2022 (USD MILLION)
  • TABLE 59: GERMANY: PGDS MARKET SIZE, BY PROCEDURE TYPE, 2015-2022 (USD MILLION)
  • TABLE 60: U.K.: PGDS MARKET SIZE, BY PROCEDURE TYPE, 2015-2022 (USD MILLION)
  • TABLE 61: FRANCE: PGDS MARKET SIZE, BY PROCEDURE TYPE, 2015-2022 (USD MILLION)
  • TABLE 62: ROE: REGULATIONS FOR INFERTILITY TREATMENT (AS OF 2016)
  • TABLE 63: ROE: PGDS MARKET SIZE, BY PROCEDURE TYPE, 2015-2022 (USD MILLION)
  • TABLE 64: ASIA-PACIFIC: MAJOR PGD AND PGS PRODUCT MANUFACTURERS AND SERVICE PROVIDERS
  • TABLE 65: ASIA-PACIFIC: PGDS MARKET SIZE, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 66: ASIA-PACIFIC: PGDS MARKET SIZE, BY PROCEDURE TYPE, 2015-2022 (USD MILLION)
  • TABLE 67: ASIA-PACIFIC: PGDS MARKET SIZE, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 68: ASIA-PACIFIC: PGDS MARKET SIZE, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 69: ASIA-PACIFIC: PGDS MARKET SIZE, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 70: ASIA-PACIFIC: PGDS MARKET SIZE FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 71: ASIA-PACIFIC: PGDS MARKET SIZE, BY END-USER, 2015-2022 (USD MILLION)
  • TABLE 72: CHINA: PGDS MARKET SIZE, BY PROCEDURE TYPE, 2015-2022 (USD MILLION)
  • TABLE 73: JAPAN: PGDS MARKET SIZE, BY PROCEDURE TYPE, 2015-2022 (USD MILLION)
  • TABLE 74: INDIA: PGDS MARKET SIZE, BY PROCEDURE TYPE, 2015-2022 (USD MILLION)
  • TABLE 75: ROAPAC: PGDS MARKET SIZE, BY PROCEDURE TYPE, 2015-2022 (USD MILLION)
  • TABLE 76: ROW: MAJOR PGD AND PGS PRODUCT MANUFACTURERS AND SERVICE PROVIDERS
  • TABLE 77: ROW: PGDS MARKET SIZE, BY PROCEDURE TYPE, 2015-2022 (USD MILLION)
  • TABLE 78: ROW: PGDS MARKET SIZE, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 79: ROW: PGDS MARKET SIZE, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 80: ROW: PGDS MARKET SIZE, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 81: ROW: PGDS MARKET SIZE FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 82: ROW: PGDS MARKET SIZE, BY END-USER, 2015-2022 (USD MILLION)
  • TABLE 83: AGREEMENTS, COLLABORATIONS, PARTNERSHIPS, AND ALLIANCES 2014-2017
  • TABLE 84: PRODUCT LAUNCHES AND APPROVALS, 2014-2017
  • TABLE 85: ACQUISITIONS, 2014-2017
  • TABLE 86: OTHER DEVELOPMENTS, 2014-2017

LIST OF FIGURES

  • FIGURE 1: GLOBAL PGDS MARKET: RESEARCH METHODOLOGY STEPS
  • FIGURE 2: BREAKDOWN OF SUPPLY-SIDE PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 3: DATA TRIANGULATION
  • FIGURE 4: PGDS MARKET SIZE, BY TECHNOLOGY, 2017-2022 (USD MILLION)
  • FIGURE 5: PGDS MARKET SIZE, BY PRODUCT & SERVICE, 2017-2022 (USD MILLION)
  • FIGURE 6: PGDS MARKET SHARE, BY PROCEDURE TYPE, 2017-2022
  • FIGURE 7: PGDS MARKET SIZE, BY APPLICATION, 2017-2022 (USD MILLION)
  • FIGURE 8: PGDS MARKET SHARE, BY END-USER, 2017-2022
  • FIGURE 9: GLOBAL PGDS MARKET SHARE, BY REGION, 2017-2022
  • FIGURE 10: DECLINING FERTILITY RATES & TECHNOLOGICAL ADVANCEMENTS IN GENETIC ANALYSIS ACTING AS KEY GROWTH DRIVERS
  • FIGURE 11: NORTH AMERICA REGION AND NGS SEGMENT DOMINATE PGDS MARKET IN 2016
  • FIGURE 12: ANEUPLOIDY SEGMENT TO DOMINATE PGDS MARKET DURING FORECAST PERIOD (USD MILLION)
  • FIGURE 13: REAGENTS & CONSUMABLES SEGMENT TO CONTINUE HOLDING LARGEST MARKET SHARE DURING FORECAST PERIOD
  • FIGURE 14: ASIA-PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 15: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 16: GLOBAL FEMALE FERTILITY RATE (2004-2015)
  • FIGURE 17: U.S. GLOBAL HEALTH FUNDING: FAMILY PLANNING/REPRODUCTIVE HEALTH, 2006-2016 (USD MILLION)
  • FIGURE 18: VALUE CHAIN ANALYSIS: PGDS MARKET, 2016
  • FIGURE 19: PORTER'S FIVE FORCES ANALYSIS: PGDS MARKET, 2016
  • FIGURE 20: U.S. FEDERAL REGULATIONS FOR GENETIC TESTING, 2016
  • FIGURE 21: PGDS MARKET, BY PROCEDURE TYPE, 2017-2022 (USD MILLION)
  • FIGURE 22: PGDS MARKET SIZE, BY TECHNOLOGY, 2017-2022 (USD MILLION)
  • FIGURE 23: PGDS MARKET, BY PRODUCT & SERVICE, 2017-2022 (USD MILLION)
  • FIGURE 24: PGDS MARKET SIZE, BY APPLICATION, 2017-2022 (USD MILLION)
  • FIGURE 25: PGDS MARKET SIZE, BY END-USER, 2017-2022 (USD MILLION)
  • FIGURE 26: GLOBAL PGDS MARKET, BY REGION
  • FIGURE 27: ASIA-PACIFIC PGDS MARKET TO RECORD HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 28: NORTH AMERICA: PGDS MARKET SNAPSHOT
  • FIGURE 29: EUROPE: PGDS MARKET SNAPSHOT
  • FIGURE 30: ASIA-PACIFIC: PGDS MARKET SNAPSHOT
  • FIGURE 31: ROW: PGDS MARKET SNAPSHOT
  • FIGURE 32: TOP 5 PLAYERS RANKING IN GLOBAL PGDS MARKET (2016)
  • FIGURE 33: AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, AND ALLIANCES THE MAJOR GROWTH STRATEGY ADOPTED BY MARKET PLAYERS FROM 2014 TO 2017
  • FIGURE 34: GLOBAL PGDS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2017
  • FIGURE 35: ILLUMINA, INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 36: THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 37: AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 38: PERKINELMER, INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 39: THE COOPER COMPANIES INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 40: ABBOTT LABORATORIES: COMPANY SNAPSHOT (2016)
  • FIGURE 41: NATERA, INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 42: COMBIMATRIX CORPORATION: COMPANY SNAPSHOT (2016)
Back to Top